These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 24872147)

  • 1. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.
    Autmizguine J; Guptill JT; Cohen-Wolkowiez M; Benjamin DK; Capparelli EV
    Drugs; 2014 Jun; 74(8):891-909. PubMed ID: 24872147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.
    Roberts JK; Stockmann C; Constance JE; Stiers J; Spigarelli MG; Ward RM; Sherwin CM
    Clin Pharmacokinet; 2014 Jul; 53(7):581-610. PubMed ID: 24871768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of antifungal agents in neonates and young infants.
    Regazzi M; Billaud EM; Lefeuvre S; Stronati M
    Curr Med Chem; 2012; 19(27):4621-32. PubMed ID: 22876899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal prophylaxis in pediatric patients undergoing therapy for cancer: drugs and dosing.
    Lehrnbecher T
    Curr Opin Infect Dis; 2015 Dec; 28(6):523-31. PubMed ID: 26381996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal agents in neonates: issues and recommendations.
    Almirante B; Rodríguez D
    Paediatr Drugs; 2007; 9(5):311-21. PubMed ID: 17927303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antifungal agents under development in children and neonates.
    Steinbach WJ; Benjamin DK
    Curr Opin Infect Dis; 2005 Dec; 18(6):484-9. PubMed ID: 16258320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
    Pea F
    Mycoses; 2020 Aug; 63(8):854-858. PubMed ID: 32472719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of antifungal agents in children.
    Watt K; Benjamin DK; Cohen-Wolkowiez M
    Early Hum Dev; 2011 Mar; 87 Suppl 1(Suppl 1):S61-5. PubMed ID: 21277714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.
    Gómez-López A
    Clin Microbiol Infect; 2020 Nov; 26(11):1481-1487. PubMed ID: 32535150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of micafungin in infants: insights into optimal dosing.
    Ascher S; Smith PB; Benjamin DK
    Expert Opin Drug Saf; 2011 Mar; 10(2):281-6. PubMed ID: 21226655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.
    Stockmann C; Constance JE; Roberts JK; Olson J; Doby EH; Ampofo K; Stiers J; Spigarelli MG; Sherwin CM
    Clin Pharmacokinet; 2014 May; 53(5):429-54. PubMed ID: 24595533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
    Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of micafungin in neonates and young infants.
    Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.
    Lestner JM; Smith PB; Cohen-Wolkowiez M; Benjamin DK; Hope WW
    Br J Clin Pharmacol; 2013 Jun; 75(6):1381-95. PubMed ID: 23126319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of invasive neonatal candidiasis.
    Botero-Calderon L; Benjamin DK; Cohen-Wolkowiez M
    Expert Opin Pharmacother; 2015 May; 16(7):1035-48. PubMed ID: 25842986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungals in systemic neonatal candidiasis.
    Frattarelli DA; Reed MD; Giacoia GP; Aranda JV
    Drugs; 2004; 64(9):949-68. PubMed ID: 15101785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.